Carisma Therapeutics, Inc. (CARM)
NASDAQ: CARM · Real-Time Price · USD
0.418
-0.024 (-5.35%)
At close: Dec 20, 2024, 4:00 PM
0.426
+0.009 (2.03%)
After-hours: Dec 20, 2024, 5:06 PM EST
Carisma Therapeutics Employees
Carisma Therapeutics had 107 employees as of December 31, 2023.
Employees
107
Change
n/a
Growth
n/a
Revenue / Employee
$189,421
Profits / Employee
-$596,262
Market Cap
17.45M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 107 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Concord Medical Services Holdings | 727 |
| Retractable Technologies | 151 |
| Bolt Biotherapeutics | 100 |
| bioAffinity Technologies | 75 |
| HCW Biologics | 45 |
| Bullfrog AI | 11 |
| CervoMed | 8 |
| Tenax Therapeutics | 6 |
CARM News
- 12 days ago - Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline - PRNewsWire
- 24 days ago - Carisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference - PRNewsWire
- 4 weeks ago - Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024 - PRNewsWire
- 6 weeks ago - Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma - PRNewsWire
- 6 weeks ago - Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - PRNewsWire
- 6 weeks ago - Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024 - PRNewsWire
- 7 weeks ago - Carisma Therapeutics Announces Changes to its Board of Directors - PRNewsWire
- 2 months ago - Carisma Therapeutics Announces Upcoming Presentations at SITC 2024 - PRNewsWire